Table 4.

Correlation of host hepatic monocytes/macrophages subtypes at the tumour-central area (TCA) or tumour infiltrating front (TIF) with clinicopathological characteristics of patients undergoing liver transplantation for hepatocellular carcinoma.

Variable	Without TACE			With TACE
	TEM+/TCA	TEM−/TCA	p	TEM+/TCA	TEM+/TCA	p
No. of patients	12	21		12	43
Age
≤60	5 (41.7%)	9 (42.9%)	0.947	2 (16.7%)	21 (48.8%)	0.395
<60	7 (58.3%)	12 (57.1%)		10 (83.3%)	22 (51.2%)
Gender
Male	8 (66.7%)	18 (85.7%)	0.198	9 (75.0%)	38 (88.4%)	0.245
Female	4 (33.3%)	63 (14.3%)		3 (25.0%)	5 (11.6%)
Graft tumour recurrence
Positive	2 (16.7%)	3 (14.3%)	0.854	1 (8.3%)	5 (11.6%)	0.746
Negative	10 (83.3%)	18 (85.7%)		11 (91.7%)	38 (88.4%)
Distant metastases
Positive	2 (16.7%)	2 (9.5%)	0.545	3 (25.0%)	6 (14.0%)	0.360
Negative	10 (83.3%)	19 (90.5%)		9 (75.0%)	37 (86.0%)
Graft rejection
With	4 (33.3%)	12 (57.1%)	0.188	2 (16.7%)	11 (25.6%)	0.520
Without	8 (66.7%)	9 (42.9%)		10 (83.3%)	32 (74.4%)
Tumour size, mm
≤20	4 (33.3%)	15 (71.4%)	0.033	8 (66.7%)	36 (83.7%)	0.192
>20	8 (66.7%)	6 (28.6%)		4 (33.3%)	7 (16.3%)
Angioinvasion
Positive	2 (16.7%)	2 (9.5%)	0.545	2 (16.7%)	4 (9.3%)	0.469
Negative	10 (83.3%)	619 (90.5%)		10 (83.3%)	39 (90.7%)
Lymphangiosis carcinomatosa
Positive	0 (0.0%)	1 (4.8%)	0.443	3 (25.0%)	4 (9.3%)	0.149
Negative	12 (100.0%)	20 (95.2%)		9 (75.0%)	39 (90.7%)
Histologic differentiation
G1 well	5 (41.7%)	10 (47.6%)	0.741	6 (50.0%)	23 (53.5%)	0.831
G2 moderate/G3 poor	7 (58.3%)	11 (52.4%)		6 (50.0%)	20 (46.5%)
Pathologic T stage
T1	10 (83.3%)	18 (85.7%)	0.854	6 (50.0%)	21 (48.8%)	0.943
T2/T3	2 (16.7%)	3 (14.3%)		6 (50.0%)	22 (51.2%)

Variable	Without TACE			With TACE
	CD68+/TCA	CD68−/TCA	p	CD68+/TCA	CD68−/TCA	p
No. of patients	12	21		16	39
Gender
≤60	5 (41.7%)	9 (42.9%)	0.947	3 (18.8%)	20 (51.3%)	0.026
<60	7 (58.3%)	12 (57.1%)		13 (81.3%)	19 (48.7%)
Gender
Male	9 (75.0%)	17 (81.0%)	0.687	13 (81.3%)	34 (87.2%)	0.571
Female	3 (25.0%)	4 (19.0%)		3 (18.8%)	5 (12.8%)
Graft tumour recurrence
Positive	3 (25.0%)	2 (9.5%)	0.854	1 (6.3%)	5 (12.8%)	0.478
Negative	9 (75.0%)	19 (90.5%)		15 (93.8%)	34 (87.2%)
Distant metastases
Positive	2 (16.7%)	2 (9.5%)	0.545	1 (6.3%)	8 (20.5%)	0.194
Negative	10 (83.3%)	19 (90.5%)		15 (93.8%)	31 (79.5%)
Graft rejection
With	6 (50.0%)	10 (47.6%)	0.895	3 (18.8%)	611 (25.6%)	0.585
Without	6 (50.0%)	11 (52.4%)		13 (81.3%)	32 (74.4%)
Tumour size, mm
≤20	4 (33.3%)	15 (71.4%)	0.033	15 (93.8%)	29 (74.4%)	0.102
>20	8 (66.7%)	6 (28.6%)		1 (6.3%)	10 (25.6%)
Angioinvasion
Positive	1 (8.3%)	3 (14.3%)	0.545	2 (12.5%)	4 (10.3%)	0.808
Negative	11 (91.7%)	18 (85.7%)		14 (87.5%)	35 (89.7%)
Lymphangiosis carcinomatosa
Positive	0 (0.0%)	1 (4.8%)	0.443	0 (0.0%)	7 (17.9%)	0.070
Negative	12 (100.0%)	20 (95.2%)		16 (100.0%)	632 (82.1%)
Histologic differentiation
G1 well	8 (66.7%)	7 (33.3%)	0.064	9 (56.3%)	20 (53.5%)	0.737
6G2 moderate/G3 poor	4 (33.3%)	14 (66.7%)		7 (43.8%)	619 (48.7%)
Pathologic T stage
T1	18 (85.7%)	10 (83.3%)	0.854	12 (75.0%)	15 (38.5%)	0.014
T2/T3	3 (14.3%)	2 (16.7%)		4 (25.0%)	24 (61.5%)
TEMs in TCA
Positive	13 (61.9%)	8 (66.7%)	0.544	34 (87.2%)	9 (56.3%)	0.012
Negative	8 (38.1%)	4 (33.3%)		5 (12.8%)	7 (43.8%)
No. of patients	5	28		45	10
Angioinvasion
Positive	2 (40.0%)	2 (7.1%)	0.038	4 (8.9%)	2 (20.0%)	0.308
Negative	3 (60.0%)	26 (92.9%)		41 (91.1%)	68 (80.0%)
Histologic differentiation
G1 well	2 (40.0%)	13 (46.4%)	0.790	27 (60.0%)	2 (20.0%)	0.022
G2 moderate/G3 poor	3 (60.0%)	15 (53.6%)		18 (40.0%)	8 (80.0%)

Variable	Without TACE			With TACE
	CD163+/TIF	CD163−/TCA	p	CD163+/TIF	CD163−/TCA	p
No. of patients	28	5		6	49
Distant metastases
Positive	2 (7.1%)	2 (40.0%)	0.038	0 (00.0%)	9 (18.4%)	0.251
Negative	26 (92.9%)	3 (60.0%)		6 (100.0%)	40 (81.6%)